Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
1998-11-16
|
| pubmed:abstractText |
While allogeneic stem cell transplantation (SCT) is curative for a significant number of patients with AML, relapse of disease within the bone marrow and/or extramedullary (EM) sites following high-dose therapy continues to limit the success of this treatment. Between October 1985 and December 1996, 81 adults underwent allogeneic SCT for de novo AML at our centre. Forty-two patients remain alive and free of leukaemia with a median follow-up of 50 months. The 5-year actuarial event-free survivals (EFS) for all patients and for those undergoing SCT in CR1 or with advanced disease were 46% (95% confidence interval (CI) 34-58%), 63% (CI 46-76%), and 19% (CI 7-36%), respectively. Twenty-two patients relapsed at a median of 8 (range 1.6-54.5) months with the actuarial risk of relapse for all, CR1 and advanced disease patients being 38%, (CI 27-52%), 23% (CI 13-40%) and 68% (CI 46-88%), respectively. Ten patients relapsed at EM sites; six of these (27% of relapses) had an isolated EM relapse at a median of 31 (range 8.5-54) months. Three of the patients with isolated EM relapse survived > or =24 months following relapse and two patients remain disease-free at 29+ and 33+ months. BuCy conditioning followed by allogeneic SCT in AML results in satisfactory EFS although there is a significant risk of late isolated EM relapse.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
0268-3369
|
| pubmed:author |
pubmed-author:BarnettM JMJ,
pubmed-author:ELOYRR,
pubmed-author:HoggeD EDE,
pubmed-author:HorsmanD EDE,
pubmed-author:KlingemannH GHG,
pubmed-author:NaimanS CSC,
pubmed-author:NantelS HSH,
pubmed-author:NevillT JTJ,
pubmed-author:ShepherdJ DJD,
pubmed-author:SimpsonD RDR,
pubmed-author:SutherlandH JHJ,
pubmed-author:TozeC LCL,
pubmed-author:VickarsL MLM
|
| pubmed:issnType |
Print
|
| pubmed:volume |
22
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
259-64
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:9720739-Adolescent,
pubmed-meshheading:9720739-Adult,
pubmed-meshheading:9720739-Busulfan,
pubmed-meshheading:9720739-Cyclophosphamide,
pubmed-meshheading:9720739-Disease-Free Survival,
pubmed-meshheading:9720739-Female,
pubmed-meshheading:9720739-Graft vs Host Disease,
pubmed-meshheading:9720739-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:9720739-Humans,
pubmed-meshheading:9720739-Immunosuppressive Agents,
pubmed-meshheading:9720739-Leukemia, Myeloid, Acute,
pubmed-meshheading:9720739-Male,
pubmed-meshheading:9720739-Middle Aged,
pubmed-meshheading:9720739-Recurrence,
pubmed-meshheading:9720739-Transplantation, Homologous,
pubmed-meshheading:9720739-Transplantation Conditioning
|
| pubmed:year |
1998
|
| pubmed:articleTitle |
High incidence of extramedullary relapse of AML after busulfan/cyclophosphamide conditioning and allogeneic stem cell transplantation.
|
| pubmed:affiliation |
Division of Hematology, British Columbia Cancer Agency, Vancouver Hospital and Health Sciences Centre, Canada.
|
| pubmed:publicationType |
Journal Article
|